Want to join the conversation?
$MRK said it continues to work to achieve manufacturing readiness to supply the EU market, with product launches estimated to begin in 4Q16 or 1Q17. The U.S. FDA approved ZEPATIER 50mg/100mg tablets in January 2016 to treat adult patients with chronic HCV genotype 1 or 4 infection, with or without ribavirin (RBV).
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?